Research ExplorerPublicationsThe 21-gene recurrence score assay impacts adjuvant therapy ...

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.

Standard

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. / Eiermann, W; Rezai, M; Kümmel, S; Kühn, T; Warm, M; Friedrichs, K; Schneeweiss, A; Markmann, S; Eggemann, H; Hilfrich, J; Jackisch, C; Witzel, Isabell; Eidtmann, H; Bachinger, A; Hell, S; Blohmer, J.

In: ANN ONCOL, Vol. 24, No. 3, 3, 2013, p. 618-624.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Eiermann, W, Rezai, M, Kümmel, S, Kühn, T, Warm, M, Friedrichs, K, Schneeweiss, A, Markmann, S, Eggemann, H, Hilfrich, J, Jackisch, C, Witzel, I, Eidtmann, H, Bachinger, A, Hell, S & Blohmer, J 2013, 'The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.', ANN ONCOL, vol. 24, no. 3, 3, pp. 618-624. <http://www.ncbi.nlm.nih.gov/pubmed/23136233?dopt=Citation>

APA

Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., & Blohmer, J. (2013). The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. ANN ONCOL, 24(3), 618-624. [3]. http://www.ncbi.nlm.nih.gov/pubmed/23136233?dopt=Citation

Vancouver

Eiermann W, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. ANN ONCOL. 2013;24(3):618-624. 3.

Bibtex

@article{a495541bb78f4ef4be99bba16a11184e,
title = "The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.",
abstract = "We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).",
author = "W Eiermann and M Rezai and S K{\"u}mmel and T K{\"u}hn and M Warm and K Friedrichs and A Schneeweiss and S Markmann and H Eggemann and J Hilfrich and C Jackisch and Isabell Witzel and H Eidtmann and A Bachinger and S Hell and J Blohmer",
year = "2013",
language = "English",
volume = "24",
pages = "618--624",
journal = "ANN ONCOL",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.

AU - Eiermann, W

AU - Rezai, M

AU - Kümmel, S

AU - Kühn, T

AU - Warm, M

AU - Friedrichs, K

AU - Schneeweiss, A

AU - Markmann, S

AU - Eggemann, H

AU - Hilfrich, J

AU - Jackisch, C

AU - Witzel, Isabell

AU - Eidtmann, H

AU - Bachinger, A

AU - Hell, S

AU - Blohmer, J

PY - 2013

Y1 - 2013

N2 - We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).

AB - We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).

M3 - SCORING: Journal article

VL - 24

SP - 618

EP - 624

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 3

M1 - 3

ER -